

# **EXHIBIT 30**



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville MD 20857

JUN 8 1995

Jasmine Shah  
Director, Regulatory Affairs  
Amide Pharmaceuticals  
101 East Main Street  
Little Falls, New Jersey 07424

Dear Mr. Shah:

The Food and Drug Administration has completed the analysis of the following products submitted for Certification pursuant to Title 21 Code of Federal Regulations (CFR) Part 310.500.

Digoxin Tablets, 0.5mg, lot 4296A  
Digoxin Tablets, 0.5mg, lot 4300A  
Digoxin Tablets, 0.5mg, lot 4301A

Digoxin Tablets, 0.25mg, lot 4330A  
Digoxin Tablets, 0.25mg, lot 4336A  
Digoxin Tablets, 0.25mg, lot 4337A

Digoxin Tablets, 0.125mg, lot 4318A  
Digoxin Tablets, 0.125mg, lot 4320A  
Digoxin Tablets, 0.125mg, lot 4322A


We are pleased to inform you that, the above referenced lots are certified for distribution.

Please continue to submit samples of Digoxin Tablets pursuant to 21 CFR 310.500.

Sincerely yours,

John P. Loh  
Branch Chief  
Product Surveillance Branch, HFD-333  
Division of Drug Quality Evaluation  
Office of Compliance  
Center for Drug Evaluation  
and Research

0008



ACTAV 001944294